The only platform that connects VA claims from initial decision to final judgment — and shows what actually wins. Search 1,850,000+ BVA decisions, CAVC appeals, 38 CFR regulations, and M21-1 policy with AI-powered analysis.
Paste any BVA decision and get a per-issue breakdown, evidence gap analysis, and a draftable argument outline — grounded in 1.85M+ real cases and government sources.
All data comes directly from official government sources: BVA decisions from va.gov, CAVC docket from the Court's eFiling system, CFR from the Electronic Code of Federal Regulations, and M21 policy from the VA's KnowVA system.
Both. Veterans can understand their own claims. VSOs, accredited agents, and attorneys get deeper research tools including advanced search, AI-powered case analysis, docket tracking, and alerts.
A new VA rule allows disability ratings to be based on how well medication controls symptoms. Learn which conditions are affected, how to protect your rating, and what veterans' advocates are saying.
A 2026 federal rule change allows the VA to consider the effectiveness of medication when assigning disability ratings. Under this rule, if medication or treatment lowers the level of disability, the rating may be based on that reduced symptom level rather than the underlying condition's severity without treatment. This fundamentally changes how conditions like PTSD (with SSRIs), hypertension (with blood pressure medication), and sleep apnea (with CPAP) could be rated. Paralyzed Veterans of America has publicly opposed the rule, stating that 'treatment to alleviate symptoms of a service-connected condition, including medication, should not be used in a way that decreases compensation for that disability.' Veterans should understand that certain conditions have specific regulatory carve-outs — for example, 38 CFR § 4.130 rates mental health conditions based on occupational and social impairment, not symptom control alone. The strategic response is to document functional limitations that persist despite treatment, obtain medical opinions addressing residual impairment, and work with an accredited representative to frame the claim around real-world impact rather than clinical symptom scores.